Cytogenetics of chronic myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 3, 2001, Pages 553-571

  Chase, Andrew ^a   Huntly, Brian J P ^b   Cross, Nicholas C P ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ABL; BCR; CML; Cytogenetics

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLELE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CELL STRUCTURE; CHROMOSOME 17; CHROMOSOME 22; CHROMOSOME 3Q; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; HUMAN; HUMAN CELL; METAPHASE CHROMOSOME; MOLECULAR DYNAMICS; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRISOMY 8;

EID: 0034752877     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0154     Document Type: Article

References (105)

1. A minute chromosome in human chronic granulocyic leukemia
2. A possible specific chromosome abnormality in human chronic myeloid leukaemia
3. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
4. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
5. The chimeric BCR-ABL gene
6. The cytogenetic scenario of chronic myeloid leukemia
7. Variant Philadelphia translocations in chronic myeloid leukemia
8. Chromosome abnormalities in CML
9. Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia
10. Cytogenetics of chronic myelogenous leukaemia
11. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival
12. Cytogenetic peculiarities in chronic myelogenous leukemia
13. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results
14. Assessing residual disease
15. Interstitial insertion of varying amounts of ABL-containing genetic material into chromosome 22 in Ph-negative CML
16. Translocation of BCR to chromosome 9: A new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia
17. Philadelphia-negative chronic myeloid leukaemia: Detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22
18. Cytogenetic and molecular analysis in Philadelphia negative CML
19. Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia chromosome negative chronic myeloid leukemia
20. Detection of the Philadelphia chromosome in interphase nuclei
21. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization
22. Combined immunophenotyping and interphase cytogenetics on cryostat sections by the new FICTION method
23. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization
24. Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system
25. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
26. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia
27. A multicenter investigation with D-FISH BCR/ABLI probes
28. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment
29. Frequent deletion of hSNF5/INII, a component of the SWI/SNF complex, in chronic myeloid leukemia
30. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy
31. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
32. Frequent and extensive deletion during the 9,22 translocation in CML
33. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: Molecular analysis, clinical characteristics, and response to therapy
34. Deletion of the 5′-ABL region: A recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia- positive chronic myeloid leukaemia patients
35. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia
36. BCR-ABL gene variants
37. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia
38. Non-random karyotypic evolution in chronic myeloid leukemia
39. Phl-positive leukaemia, including chronic myelogenous leukaemia
40. Cytogenetics of chronic myelogenous leukemia
41. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia
42. Value of cytogenetic studies in prediction of acute phase CML
43. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression
44. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
45. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients
46. A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia
47. Chronic myelogenous leukemia in blast crisis: Retrospective analysis of prognostic factors in 90 patients
48. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: Report of 12 cases and review of the literature
49. Chromosomal abnormalities in lymphoid crisis of chronic myelogenous leukemia
50. Chronic granulocytic leukemia: Correlation of blastic transformation type with karyotypic evolution
51. Correlation between chromosomal abnormalities and blast phenotype in the blast crisis of Ph-positive CGL
52. Cytogenetic and immunogenotypic alterations of blast crisis cells in chronic myelogenous leukemia independently linked to immunophenotypic expression
53. Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic leukemia
54. Abnormalities of 3q21 and 3q26 in myeloid malignancy: A United Kingdom Cancer Cytogenetic Group study
55. The EVII gene in myeloid leukemia
56. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia
57. Recurrent appearance of 14q+ chromosome associated with lymphoid crisis of Ph-positive chronic myelogenous leukemia
58. Genotypic and cytogenetic study of acute myelocytic leukemia and chronic myelocytic leukemia in blast crisis: Specific delta rearrangement pattern does not involve J delta gene locus
59. Comparative analysis of G-banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis
60. Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: Implication of 1q12-21
61. Allelotype analysis in the evolution of chronic myelocytic leukemia
62. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia
63. MYC amplification in two further cases of acute myeloid leukemia with trisomy 4 and double minute chromosomes
64. Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes
65. Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia
66. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia
67. Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase
68. Trisomy II: An association with stem progenitor cell immunophenotype
69. Acute myeloid leukemia with trisomy II: A molecular cytogenetic study
70. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement
71. High incidence of biallelic point mutations in the runt domain of the AMLI/PEBP2alphaB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21
72. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p
73. Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation
74. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations
75. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia
76. A Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia
77. Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: Cytogenetic analysis of 24 patients
78. Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase
79. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation
80. Cytogenetic follow-up after allogeneic bone-marrow transplantation for PhI-positive chronic myelogenous leukemia
81. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia
82. Donor cell leukemia: Report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature
83. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia
84. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: A Southwest Oncology Group study (SWOG-8612)
85. Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia
86. Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia
87. Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies
88. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia
89. UK Medical Research Council randomised, multicentre trial of interferon- alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response
90. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: A new strategy for remission assessment
91. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: Comparison with metaphase banding analysis
92. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy
93. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: Comparison with the frequency detected in cycling cells of the bone marrow
94. Chromosomal aberrations during interferon therapy for chronic myelogenous leukemia
95. Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha
96. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: Report of three cases
97. Trisomy 8 in Philadelphia chromosome (PhI)-negative cells in the course of PhI-positive chronic myelocytic leukemia
98. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia
99. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia
100. Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome
101. Acute blast transformation in CML patients still showing cytogenetic response to IFN-alphanI and the presence of cytogenetic abnormalities in Ph negative cells
102. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of PhI-positive chronic myelogenous leukemia
103. A. Evidence for a multistep pathogenesis of chronic myelogenous leukemia
104. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia
105. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia